Study, year(ref.) | Pre-operative radiotherapy | Liver transplantation | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
No. of patients /lesions | Child–Pugh class | Dose (Gy)/no. of fractions | Infield control rate (%) | Toxicity ≥ grade 3/RILD | No. of patient | Median time to LT (months) | Pathologic response | Post-transplant outcome | Median follow-up (months) | |
Sandroussi, 2010 [8] | 10/10 | A: 40% B: 50% C: 10% | 33/1–6 | 100% | 0/0 | 5 | 5.2 | SpR: 3 (60%) MpR: 1 (20%) NpR: 1 (20%) | 6-month RFS: 70% | 6 |
Andolino, 2011 [9] | 60/NA | A: 60% B: 40% | 40–44/3 | NA | 21/NA | 23 | 7 | NA | 2-year OS: 96% 2-year PFS: 69% | 27 |
Katz, 2011 [10] | 18/21 | A: 17% B: 44% C: 22% NA:17% | 50/10 | 100% | 1/0 | 11 | 6 | CpR: 2 (18.1%) SpR: 3 (27.2%) MpR 4 (36.6%) NpR: 2 (18.1%) | 1 liver recurrence 10 alive with NED | 19.6 |
O'Connor, 2012 [11] | 10/11 | A: 70% B: 20% C: 10% | 51/3 | 100% | 0/0 | 10 | 3.8 | NpR: 3 (30%) | 5-year OS: 100% 5-year DFS: 100% | 62 |
Guarneri, 2016 [12] | 8/13 | A: 62% B: 38% | 36–48/3–5 | 100% | 0/1 | 8 | 3.2 | CpR: 8 (61.5%) SpR: 1 (7.7%) MpR: 2 (15.3%) NpR: 2 (15.3%) | No liver recurrence 7 alive with NED | 9.6 |
Moore, 2017 [13] | 23/NA | A: 57% B: 43% | 30/5 48/4 54/3 | 100% | 0/1 | 11 | 4.8 | CpR: 3 (27.3%) SpR: 6 (54.5%) MpR: 2 (18.2%) | Median OS: not reached Median PFS: not reached | 12 |
Mannina, 2017 [14] | 38/51 | A: 45% B: 55% | 36–45/3–5 | NA | NA/NA | 38 | 8.8 | CpR: 45% | 1, 2, 3, 5-year OS: 92%, 86%, 77%, 73% 1, 2, 3, 5-year DFS: 91%, 85%, 74%, 74% | 58 |
Gresswell, 2018 [15] | 12/17 | B: 58% C: 42% | 40/5 | 100% | 0/0 | 11 | 5 | CpR: 46% | 1,2,3,4-year OS: 91%, 91%, 68%, 57% | 40 |
Sapisochin, 2017 [16] | 36/NA | A: 61% B: 39% | 36/6 | NA | NA/NA | 30 | 5.2 | CpR: 4 (13.3%) SpR: 12 (40%) MpR: 11 (36.7%) NpR: 3 (10%) | 1,3,5-year OS: 83%, 75%,75% | 29.6 |
Present series | 14/26 | A: 79% B: 14% C: 7% | 45/5 | 100% | 4/1 | 14 | 8.4 | CpR: 3 (27.3%) SpR: 3 (27.3%) MpR: 5 (45.4%) | Median OS: 37.8 months Median RFS: 18.3 months | 30.2 |